17,000

UK employees including 15,300 at these sites

Montrose and Irvine

900 employees

Manufacturing

Barnard Castle

1,400

Manufacturing

Ulverston

360

Manufacturing

Ware

2,400

Manufacturing

and research and

development

Stevenage

2,500

Research and

development

Uxbridge

1,700

HQ

Maidenhead

560

Manufacturing

Brentford

4,200

HQ

Worthing

840

Manufacturing

Weybridge

450

Manufacturing

The threat of a no-deal Brexit is forcing a number of companies including GSK, the UK’s biggest drugmaker, to build new laboratories for parallel product testing and shift licences to ensure their products can still be sold in the EU.

 

The firm, which makes the shingles vaccine Shingrix, is spending up to £70m on a host of measures including securing more warehouse space. A no-deal Brexit could add £50m a year in tariff costs.

GSK says it is making good progress but getting its plans in place before the 29 March deadline is going to be ‘ambitious’.

17,000

Montrose and Irvine

900 employees

Manufacturing

UK employees including 15,300 at these sites

The threat of a no-deal Brexit is forcing a number of companies including GSK, the UK’s biggest drugmaker, to build new laboratories for parallel product testing and shift licences to ensure their products can still be sold in the EU.

 

The firm, which makes the shingles vaccine Shingrix, is spending up to £70m on a host of measures including securing more warehouse space. A no-deal Brexit could add £50m a year in tariff costs.

GSK says it is making good progress but getting its plans in place before the 29 March deadline is going to be ‘ambitious’.

Edinburgh

Barnard Castle

1,400

Manufacturing

Ware

2,400

Manufacturing

and research and

development

Ulverston

360

Manufacturing

Stevenage

2,500

Research and

development

Uxbridge

1,700

HQ

Uxbridge

1,700

HQ

Brentford

4,200

HQ

Maidenhead

560

Manufacturing

Weybridge

450

Manufacturing

Worthing

840

Manufacturing